Oculis announced that CEO Riad Sherif will present Licaminlimab, a novel topical anti-TNFα candidate for TNFR1-mediated dry eye disease, at Eyecelerator @ AAO 2026 on October 8. The company's PREDICT-1 registrational trial is on track for topline readout around year-end. Oculis will also sponsor the Neuro-Ophthalmology Subspecialty Day, highlighting its commitment to advancing neuro-ophthalmology research and innovation.

Halozyme Therapeutics shares rose 3.3% to $115.13 on strong volume, driven by investor optimism around its ENHANZE drug-delivery technology collaborations with major pharmaceutical companies. The company is expected to report quarterly earnings of $2.25 per share (+30.8% YoY) and revenues of $470.95 million (+32.9% YoY). With a 2.6% upward revision in consensus EPS estimates over the past 30 days and a Zacks Rank #2 (Buy) rating, analysts suggest monitoring the stock for potential continued strength.

Oculis Holding AG announced it will present Privosegtor, a novel neuroprotective therapy candidate, at Clinical Trials at the Summit 2026 on June 13, 2026. The presentation will highlight Privosegtor's development journey from discovery through the PIONEER registrational trials for optic neuritis treatment. The drug has received Breakthrough Therapy and PRIME designations and showed positive Phase 2 ACUITY trial results.

Oculis announced a presentation at Clinical Trials at the Summit 2026 on its investigational drug Privosegtor, a neuroprotective therapy candidate for optic neuritis. The company highlighted positive Phase 2 ACUITY trial results and regulatory milestones including FDA Breakthrough Therapy designation and EMA PRIME designation, as it advances the PIONEER registrational program.

The Schall Law Firm is investigating Oculis Holding AG for potential securities law violations. The company previously stated its Phase 3 DIAMOND trials were 'advancing as planned,' but announced on May 29, 2026, that both trials failed to meet primary endpoints, leading to the decision not to pursue FDA filing for its drug candidate. Investors are invited to join the class action lawsuit.

Oculis announced that its OCS-01 eye drops failed to meet the primary endpoint of improving visual acuity in two Phase 3 trials for diabetic macular edema (DME), though secondary endpoints showed significant retinal thickness reduction. The company will not pursue FDA approval for OCS-01 for DME and will redirect resources toward its PIONEER trial for Privosegtor and PREDICT-1 trial for Licaminlimab.

Oculis announced that its Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops failed to meet the primary endpoint of improved best corrected visual acuity (BCVA) in diabetic macular edema patients at week 52, despite showing substantial retinal thickness reduction. The company will not pursue FDA filing for OCS-01 in DME and will redirect resources to its Privosegtor and Licaminlimab programs. Oculis maintains a strong financial position with $278 million in cash runway into 2H 2029.

Oculis received FDA approval for a Special Protocol Assessment (SPA) agreement for PIONEER-1, a Phase 3 registrational trial evaluating Privosegtor for optic neuritis treatment. The agreement validates the trial design and planned analysis for future NDA submission. Privosegtor previously received FDA Breakthrough Therapy and EMA PRIME designations, with Phase 2 ACUITY trial showing substantial vision improvements and favorable safety profile.

Oculis announced it has received FDA approval for a Special Protocol Assessment (SPA) agreement for PIONEER-1, a Phase 3 registrational trial evaluating Privosegtor for optic neuritis treatment. The SPA confirms the trial design is adequate to support a future NDA submission. Privosegtor previously received FDA Breakthrough Therapy and EMA PRIME designations, addressing a significant unmet medical need in a potential $7 billion U.S. market.

Oculis announced findings from the DME AWARE Delphi study presented at ARVO 2026, highlighting unmet needs in diabetic macular edema (DME) management. The study confirms strong expert consensus for non-invasive treatment options for early intervention. Oculis is on track to report topline results in June 2026 from its DIAMOND Phase 3 trials with OCS-01, aiming to be the first eye drop therapy for DME.

Oculis announced findings from the DME AWARE Delphi study highlighting unmet needs in diabetic macular edema (DME) management, particularly the need for non-invasive treatment options for early intervention. The study, presented at ARVO 2026, found that 60% of DME patients remain untreated one year after diagnosis due to invasive current therapies, and 40% of anti-VEGF treated patients show inadequate response. Oculis is on track to report Phase 3 results for OCS-01, a potential first-in-class eye drop therapy for DME, in June 2026.

Oculis announced it will present at the ARVO 2026 Annual Meeting, highlighting its late-stage pipeline including OCS-01 eye drops for diabetic macular edema with Phase 3 topline results anticipated in June 2026, Privosegtor for optic neuropathies, and Licaminlimab for dry eye disease. The company will showcase recent regulatory milestones and clinical data demonstrating the transformative potential of its therapies.